Evidence map›Paper›PMID 23591404›Full record

ArticleEuropean journal of human genetics : EJHG2014

Kernel canonical correlation analysis for assessing gene-gene interactions and application to ovarian cancer.

Nicholas B Larson, Gregory D Jenkins, Melissa C Larson, Robert A Vierkant, Thomas A Sellers, Catherine M Phelan, Joellen M Schildkraut, Rebecca Sutphen, Paul P D Pharoah, Simon A Gayther and 4 more

Open access · hybridAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.1field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Observational
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 7 institutions in 2 countries.

Nicholas B LarsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Gregory D JenkinsDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Melissa C LarsonDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Robert A VierkantDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Thomas A SellersCancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Catherine M PhelanCancer Epidemiology, Moffitt Cancer Center, Tampa, FL, USA.
Joellen M SchildkrautDuke Comprehensive Cancer Center, Duke University, Durham, NC, USA.
Rebecca SutphenDepartment of Pediatrics, Universty of South Florida College of Medicine, Tampa, FL, USA.
Paul P D PharoahDepartment of Oncology, University of Cambridge, Cambridge, UK.
Simon A GaytherDepartment of Preventative Medicine, University of Southern California, Los Angeles, CA, USA.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA.
Ovarian Cancer Association Consortium
Ellen L GoodeDepartment of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Brooke L Fridley1] Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA [2] Department of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
Mayo Clinic in Florida · USMoffitt Cancer Center · USDuke University · USFlorida College · USNational Cancer Institute · USUniversity of Cambridge · GBUniversity of Southern California · US

Funding

Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI Felicity Enders · 1985 to 2026
$151.3M
Hormone-Related CancersZIACP010126 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI GIERACH, GRETCHEN · 2009 to 2025
$103.5M
TRANSLATIONAL RESEARCHP30CA076292 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI KENNETH Lynn WRIGHT · 1998 to 2026
$93.5M
Transgenic & Gene-Targeting Shared ResourceP30CA168524 · NCI · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NICOLE L NOLLEN · 2012 to 2026
$40.1M
Use of microfluidic tumor cultures to enable clinical trials of therapies for ovarian cancerP50CA136393 · NCI · MAYO CLINIC ROCHESTER · PI Zhenkun Lou · 2009 to 2026
$37.0M
Ovarian cancer GWAS discovery, expansion and replication (N2 - Project #1)U19CA148112 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2010 to 2014
$10.2M
Haplotype-Based Genome Screen for Ovarian Cancer LociR01CA114343 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI SELLERS, THOMAS A · 2007 to 2011
$7.5M
The Mitochondrial Genome and Ovarian Cancer RiskR01CA149429 · NCI · H. LEE MOFFITT CANCER CTR & RES INST · PI PHELAN, CATHERINE · 2010 to 2015
$3.1M
Population-Based Analysis of Ovarian Cancer BiomarkersR01CA106414 · NCI · UNIVERSITY OF SOUTH FLORIDA · PI SUTPHEN, REBECCA · 2005 to 2009
$3.0M
Genetic Variation in the NF-kappaB Pathway and Ovarian Cancer EtiologyR01CA122443 · NCI · MAYO CLINIC ROCHESTER · PI GOODE, ELLEN L. · 2007 to 2012
$2.7M
Integrative genomic models for analysis of pharmacogenomic studiesR21CA140879 · NCI · MAYO CLINIC ROCHESTER · PI FRIDLEY, BROOKE L · 2009 to 2010
$299k
Bayesian hierarchical nonlinear models for pharmacogenomic cytotoxicity studiesR21GM086689 · NIGMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI FRIDLEY, BROOKE L · 2011 to 2012
$232k
Cancer Research UK 10124Cancer Research UK 16561Cancer Research UK C490/A10119NCI NIH HHS CA106414NCI NIH HHS CA114343NCI NIH HHS CA122443NCI NIH HHS CA136393NCI NIH HHS CA140879NCI NIH HHS CA168524NCI NIH HHS P30 CA015083NCI NIH HHS P30 CA076292NCI NIH HHS P30 CA168524NCI NIH HHS P50 CA136393NCI NIH HHS R01 CA106414NCI NIH HHS R01 CA114343NCI NIH HHS R01 CA122443NCI NIH HHS R01 CA149429NCI NIH HHS R21 CA140879NCI NIH HHS U19 CA148112NCI NIH HHS U19-CA148112NIGMS NIH HHS GM86689NIGMS NIH HHS R21 GM086689
6 · The paper itself

Abstract

Although single-locus approaches have been widely applied to identify disease-associated single-nucleotide polymorphisms (SNPs), complex diseases are thought to be the product of multiple interactions between loci. This has led to the recent development of statistical methods for detecting statistical interactions between two loci. Canonical correlation analysis (CCA) has previously been proposed to detect gene-gene coassociation. However, this approach is limited to detecting linear relations and can only be applied when the number of observations exceeds the number of SNPs in a gene. This limitation is particularly important for next-generation sequencing, which could yield a large number of novel variants on a limited number of subjects. To overcome these limitations, we propose an approach to detect gene-gene interactions on the basis of a kernelized version of CCA (KCCA). Our simulation studies showed that KCCA controls the Type-I error, and is more powerful than leading gene-based approaches under a disease model with negligible marginal effects. To demonstrate the utility of our approach, we also applied KCCA to assess interactions between 200 genes in the NF-κB pathway in relation to ovarian cancer risk in 3869 cases and 3276 controls. We identified 13 significant gene pairs relevant to ovarian cancer risk (local false discovery rate <0.05). Finally, we discuss the advantages of KCCA in gene-gene interaction analysis and its future role in genetic association studies.

Indexed as

Epistasis, GeneticHigh-Throughput Nucleotide SequencingComputational BiologyFemaleGenetic Predisposition to DiseaseHumansNF-kappa BOvarian NeoplasmsPolymorphism, Single NucleotideRisk FactorsSoftwareNF-kappa B

Identifiers

PMID23591404
PMCPMC3865403
OpenAlexW2041713290

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.